T he article by Jarvik et al, 1 appearing in this issue, illustrates the pros and cons of using a large panel of SNPs for probing deeper into the association between serum paraoxonase (PON1) and vascular disease. The obvious advantages of using such a series of convenient genetic markers are somewhat compromised in this instance by the presence of several, long-ago established recombination sites within the human PON1 genetic sequence. Appreciable linkage disequilibrium (LD) exists within conserved segments for short stretches of the PON1 gene, so that representative residues from several of these contiguous segments constitute distinctive haplotypes. However, Jarvik et al 1 have found that none of these genetic markers show any high degree of association with cardiovascular disease. The authors conclude that finding a reduced level of serum PON1 enzymatic activity still seems to be the best indicator of some important relationship between the serum PON1 enzyme and cardiovascular disease.
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Analytical techniques that identify meaningful associations between particular enzymes and a complex, multifactorial disease such as cardiovascular disease should be very useful. The article by Jarvik et al 1 used 60 selected SNPs, representing nucleotides of the PON1 gene distributed from the 5Ј-regulatory region to the 3Ј-untranslated region, covering a span of Ϸ26 kb. The SNPs selected include representatives from several regions of high internal LD. However, the above-mentioned recombination sites within the overall sequence meant that the resulting haplotypes are less informative than would be expected. It was also hoped that polymorphisms within the noncoding regions would be directly involved, or closely linked to major sites of regulatory activity, so that detailed structural analyses of these regions of the PON1 gene might predict the level of functional (enzymatic) activity. Because the level of PON1 enzymatic activity seems to be the critical measure for relating PON1 to CVD, it was disappointing to find that this also did not work out with the multiple SNP analyses. It appears that no single SNP in the DNA sequence serves as a reliable marker for predicting the level of PON1 enzymatic activity in human serum.
Human PON1 Polymorphisms and Point Mutations
Our knowledge of the polymorphic sites for human PON1 has recently been greatly expanded. A major contribution has been the complete sequencing of the PON1 gene from 23 individuals ( , which appears to be associated with low PON1 activity (see Tables  1 and 2 ). Of course, the number of individual PON1 genes sequenced, to date, is still very small, and as the number grows, more examples of PON1 variants will certainly be discovered. We can also expect to find that some of the "polymorphisms" will have to be reclassified as rare mutations, as additional sequencing information becomes available. Fortunately, PON1 activity can conveniently be directly measured in the serum or plasma. Also, the enzyme is very stable in serum properly frozen for several years. The enzyme is well preserved in heparinized plasma, though less so when citrate is used as the anticoagulant, but it is quickly and irreversibly inactivated by EDTA. Opinions differ today, however, about which PON1 substrates should be used in correlative studies with CVD. Arylesterase activity with phenyl acetate gives about equal weight to both the Q and R isozymes, because both have about the same specific activity. Diazoxon hydrolysis (DZOase) favors somewhat the Q isozyme, and paraoxon hydrolysis (POase) considerably favors the R isozyme; the degree of this bias depends on the pH selected for the assay, as well as the salt concentration. Since it is still not known what substrate best represents the "protective" role of PON1 in connection with cardiovascular disease, this important issue remains unresolved (see Navab et al 5 Jarvik et al 1 used all three substrates and found the correlation with CVD to be best with DZOase activity. However, it is not clear whether this means that the Q isozyme is intrinsically more protective than the R isozyme, or perhaps the Q isozyme is a little more stable during its protective reaction.
Future Directions
The conclusion in the article by Jarvik et al 1 that the level of PON1 activity is the best predictor of vascular disease should encourage other workers in this field to continue in this direction, rather than search for key SNPs to advance the field, at this time. In the past analysis of pharmacogenetic and hereditary metabolic conditions, it generally has been found most profitable to first make use of patient phenotypes, use these to identify the critical genotypes, and then determine the molecular basis of the association (rather than expect to reach this goal directly by genotypic surveys with SNPs.). The importance of focusing on phenotypes in such clinical investigations has recently been well defended by Weiss and Buchanan. 8 We anticipate that there are a number of critical mutations and some polymorphic sites that exert major influences on the level and quality of PON1 enzymatic activity. The Jarvik group selected several people who have relatively low arylesterase or DZOase activity and found them to be heterozygous for a defective PON1 variant. 2 If the relationship between the level of PON1 activity and cardiovascular pathology holds up, people with relatively low PON1 enzymatic activity will be found in higher numbers among the CVD patients. Our laboratory has found one such older male cardiovascular disease patient with no detectable serum paraoxonase or arylesterase activity, so we can be sure that a genetic defect resulting in a complete lack of PON1 enzymatic activity can be tolerated in man, just as has been observed for the PON1 knockout mice. 9 Our surrogate substrates for PON1 activity should still be useful in identifying low-activity phenotypes so these can be characterized, and family studies be undertaken to look for the rarer homozygous or compound heterozygous individuals with essentially no PON1 enzymatic activity. Eventually, we will need new substrates more indicative of the protective role that PON1 seems to play in protecting against oxidative damage in vivo, and switch to these assays later, rather than rely on the standard ones for PON1 hydrolytic activity. The standard hydrolytic assays will serve, for now, to identify gross reductions in enzymatic protein, even though they cannot be expected to measure the special qualitative properties of the enzyme required for protection against oxidative damage in cardiovascular tissues. 
